Dave & Buster's Entertainment reported a quarterly loss alongside declining sales, triggering a 12% drop in its share price to $7.43. The pressure was similarly acute for Kestra Medical Technologies, where shares fell 10% to $21.76 as the company posted a loss that exceeded analyst expectations.
In section Market Quotes
Market Reaction: Dave & Buster's and Kestra Lead After-Hours Declines
A volatile after-hours session saw investors retreat from Dave & Buster's and Kestra Medical following disappointing quarterly results, while clinical trial setbacks weighed on Contineum Therapeutics. Amid this broad sell-off, Boxlight emerged as a rare outlier, climbing after confirming its return to Nasdaq listing compliance.
Contineum Therapeutics faced its own headwinds after a clinical trial for a new depression treatment failed to reach its primary endpoint. The announcement pushed the stock down 4% to $14.30. Conversely, Boxlight provided a moment of stability for traders, rising 6% to $5.75 after the company successfully restored its compliance with Nasdaq listing requirements.
Comments (0)
No comments yet. Be the first!